Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases

Front Bioeng Biotechnol. 2024 Jan 18:12:1349077. doi: 10.3389/fbioe.2024.1349077. eCollection 2024.

Abstract

Gene therapy is a technique that rectifies defective or abnormal genes by introducing exogenous genes into target cells to cure the disease. Although gene therapy has gained some accomplishment for the diagnosis and therapy of inherited or acquired cardiovascular diseases, how to efficiently and specifically deliver targeted genes to the lesion sites without being cleared by the blood system remains challenging. Based on nanotechnology development, the non-viral vectors provide a promising strategy for overcoming the difficulties in gene therapy. At present, according to the physicochemical properties, nanotechnology-based non-viral vectors include polymers, liposomes, lipid nanoparticles, and inorganic nanoparticles. Non-viral vectors have an advantage in safety, efficiency, and easy production, possessing potential clinical application value when compared with viral vectors. Therefore, we summarized recent research progress of gene therapy for cardiovascular diseases based on commonly used non-viral vectors, hopefully providing guidance and orientation for future relevant research.

Keywords: cardiovascular disease; gene therapy; gene transfer; nanotechnology; non-viral vector.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Yantai Science and Technology Plan Project (No: 2022MSGY074 for JL), Shandong Natural Science Foundation Youth Program (No: ZR2022QC133 for ZS).